Drug Discovery in Japan Investigating the Sources of Innovation /

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Nagaoka, Sadao (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Singapore : Springer Singapore : Imprint: Springer, 2019.
• Έκδοση: 1st ed. 2019.
• Θέματα: Economic policy.; Management.; Industrial management.; Japan-History.; R & D/Technology Policy.; Innovation/Technology Management.; History of Japan.

This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018...

Πίνακας περιεχομένων:

• Foreword
• Acknowledgement
• Chapter 1: Introduction
• Chapter 2: Compactin
• Chapter 3: Pravastatin (Pravachol, Mevalotin)
• Chapter 4: Rosuvastatin(Crestor)
• Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur)
• Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit)
• Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC)
• Chapter 8: Pranlukast (Onon)
• Chapter 9: Tacrolimus (Prograf)
• Chapter 10: Pioglitazone (Actos, Glustin)
• Chapter 11: Donepezil (Aricept)
• Chapter 12: Candesartan (Blopress, Atacand)
• Chapter 13: Tocilizumab (Actemra,Ro-actemra)
• Chapter 14: Nivolumab (Opdivo)
• Chapter 15: Sources of innovation of drug discovery in Japan and its implications.